Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Very Bearish -75

Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”

🗣️ Jim Cramer stated his opinion that investors do not need Agilent Technologies stock at this time.

📉 He compared the company's recent struggles to Danaher, suggesting it has stopped working effectively as a growth vehicle.

🔬 Agilent provides instruments and services for biotech, diagnostics, chemical analysis, and laboratory automation.

📈 The stock was previously a great growth vehicle before COVID but soared during the pandemic period.

⚠️ Since the pandemic receded, the stock has become choppy as life sciences companies have saturated their equipment needs.

🧠 Cramer notes that life sciences companies had all the equipment they needed for years, putting the group in a difficult position.

🤖 The commentary suggests AI stocks offer greater upside potential with less downside risk compared to Agilent.

💼 There is a promotional mention of a free report on short-term AI stocks benefiting from tariffs and onshoring trends.

📅 Cramer's discussion about Agilent's performance took place around December 1, 2025, following Thanksgiving.

⚠️ No disclosure was made regarding potential conflicts of interest in the article.

Bullish Signals
  • Jim Cramer highlighted Agilent Technologies' strong historical performance, noting it was 'a thing of beauty' on its stock chart during the decade before COVID.
  • The stock roared higher during the pandemic, demonstrating resilient growth even as a key supplier to the life sciences industry.
  • Agilent provides essential instruments and software for critical sectors including biotech, diagnostics, and chemical analysis.
  • Cramer described Agilent as an 'arms dealer to the life sciences industry,' underscoring its fundamental importance and market position.
Risk Factors
  • Jim Cramer explicitly states 'I Don't Think You Need It', comparing Agilent Technologies to Danaher, which he notes 'stopped working' as an investment vehicle.
  • Agilent's performance has been 'choppy' since the pandemic receded, reflecting a broader industry downturn where life sciences companies overspent on equipment years ago.
  • Cramer suggests investors could find greater upside potential and less downside risk in other AI stocks rather than holding Agilent.
  • The stock was previously known as a 'great growth vehicle' but that positive trajectory ended before the pandemic when it began declining.
Full Analysis
Jim Cramer recently addressed investor concerns regarding Agilent Technologies, Inc. (NYSE:A), describing the stock as essential to life sciences due to its extensive test and measurement capabilities in biotech. He compared Agilent to Danaher, suggesting that while both companies play significant roles in their sectors, he personally believes investors do not need these particular holdings. Cramer noted that Agilent, long recognized by its ticker symbol 'A', was once a premier growth vehicle with an impressive chart performance during the decade preceding the pandemic and again during the pandemic boom. However, since the receding of pandemic-related demand for life sciences equipment, Cramer observes that the industry as a whole has faced challenging conditions. He explains that many life sciences companies accumulated excess inventory and equipment needs over several years, leading to choppy stock performance for the sector. This broader context of oversaturation in the industry has weighed on Agilent's recent trajectory, contributing to its current status in the market. Beyond his specific comments on Agilent, Cramer included a general investment strategy note suggesting that investors seeking better opportunities might consider AI stocks instead. He argues that certain AI investments offer greater upside potential with less downside risk than traditional industrial names like Agilent. This perspective is coupled with a promotional mention of an external report focusing on undervalued AI stocks poised to benefit from Trump-era tariffs and the broader onshoring trend, though he provided no specific disclosure regarding financial positions or conflicts of interest at the time of the commentary.